Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Given Consensus Rating of “Hold” by Brokerages

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) has been assigned an average rating of “Hold” from the eight ratings firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $36.50.

A number of research analysts have recently weighed in on the company. UBS Group restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. Royal Bank Of Canada raised their price objective on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the company a “sector perform” rating in a research report on Tuesday, February 24th. Raymond James Financial restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. Weiss Ratings raised shares of Lakefront Biotherapeutics American Depositary Shares from a “sell (d)” rating to a “hold (c)” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen lowered shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

Several hedge funds have recently made changes to their positions in LKFT. Bank of America Corp DE increased its stake in Lakefront Biotherapeutics American Depositary Shares by 2.1% during the third quarter. Bank of America Corp DE now owns 30,949 shares of the biotechnology company’s stock worth $1,072,000 after acquiring an additional 643 shares during the last quarter. Van ECK Associates Corp increased its stake in Lakefront Biotherapeutics American Depositary Shares by 61.6% during the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 750 shares during the last quarter. Two Sigma Investments LP increased its stake in Lakefront Biotherapeutics American Depositary Shares by 3.7% during the third quarter. Two Sigma Investments LP now owns 22,459 shares of the biotechnology company’s stock worth $778,000 after acquiring an additional 800 shares during the last quarter. State of Wyoming bought a new stake in Lakefront Biotherapeutics American Depositary Shares during the second quarter worth approximately $28,000. Finally, Arax Advisory Partners increased its stake in Lakefront Biotherapeutics American Depositary Shares by 319.2% during the fourth quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock worth $76,000 after acquiring an additional 1,778 shares during the last quarter. 32.46% of the stock is currently owned by hedge funds and other institutional investors.

Lakefront Biotherapeutics American Depositary Shares Stock Up 0.2%

Shares of Lakefront Biotherapeutics American Depositary Shares stock opened at $27.73 on Thursday. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -19.67 and a beta of 0.25. The business has a 50-day moving average price of $28.87 and a 200-day moving average price of $31.42. Lakefront Biotherapeutics American Depositary Shares has a twelve month low of $26.42 and a twelve month high of $37.78.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The firm had revenue of $1.06 billion for the quarter. On average, equities analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.